VerImmune is developing a groundbreaking "virus-inspired"particle (ViP) non-viral delivery platform that self-assembles, offering transformative potential for therapeutic applications. Our lead program, VERI-101, uniquely redirects past viral memory to target and kill cancer cells, providing a differentiated approach in oncology. We anticipate submitting our IND for VERI-101 in H2 2025, positioning us at the forefront of innovation in cancer treatment. We've also previously established early R&D partnerships with notable companies like Fosun Pharmaceutical and Janssen Biologics, resulting in over $3M in revenue since 2022. Verimmune is currently raising an $8 million Pre-Series A round and has completed its first closing of $4.5 million, We are now finalizing the second closing syndicate and would love to present the technology and pipeline to you.